Powered by

BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017

MAINZ, Germany, March 07, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 5 in Washington, DC. This is the first example of a clinically applied systemic mRN

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox